- Home
- CUBI vs GLPG Comparison
CUBI vs GLPG Comparison
Compare CUBI & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUBI
- GLPG
- Stock Information
- Founded
- CUBI 1994
- GLPG 1999
- Country
- CUBI United States
- GLPG Belgium
- Employees
- CUBI N/A
- GLPG N/A
- Industry
- CUBI Major Banks
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- CUBI Finance
- GLPG Health Care
- Exchange
- CUBI Nasdaq
- GLPG Nasdaq
- Market Cap
- CUBI 1.7B
- GLPG 2.0B
- IPO Year
- CUBI 2012
- GLPG 2005
- Fundamental
- Price
- CUBI $63.29
- GLPG $32.78
- Analyst Decision
- CUBI Buy
- GLPG Sell
- Analyst Count
- CUBI 9
- GLPG 4
- Target Price
- CUBI $67.38
- GLPG $25.33
- AVG Volume (30 Days)
- CUBI 374.6K
- GLPG 233.1K
- Earning Date
- CUBI 07-24-2025
- GLPG 07-23-2025
- Dividend Yield
- CUBI N/A
- GLPG N/A
- EPS Growth
- CUBI N/A
- GLPG N/A
- EPS
- CUBI 3.98
- GLPG N/A
- Revenue
- CUBI $591,500,000.00
- GLPG $311,493,731.00
- Revenue This Year
- CUBI $12.60
- GLPG $0.78
- Revenue Next Year
- CUBI $10.57
- GLPG N/A
- P/E Ratio
- CUBI $16.05
- GLPG N/A
- Revenue Growth
- CUBI N/A
- GLPG 18.32
- 52 Week Low
- CUBI $40.75
- GLPG $22.36
- 52 Week High
- CUBI $68.49
- GLPG $33.10
- Technical
- Relative Strength Index (RSI)
- CUBI 63.33
- GLPG 79.17
- Support Level
- CUBI $61.49
- GLPG $30.75
- Resistance Level
- CUBI $65.46
- GLPG $30.78
- Average True Range (ATR)
- CUBI 1.93
- GLPG 0.64
- MACD
- CUBI -0.30
- GLPG 0.31
- Stochastic Oscillator
- CUBI 33.22
- GLPG 93.78
About CUBI Customers Bancorp Inc
Customers Bancorp Inc is a bank holding company engaged in banking activities. It provides financial products and services to small and middle-market businesses, not-for-profits, and consumers. The company operates in Lending Activities, Commercial Lending, Consumer Lending, Private Banking, Deposit Products, Other Funding Sources and Financial Products and Services. The majority of revenue is derived from commercial lending.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.